<p>Yesterday, Spark Therapeutics, Inc (NASDAQ:ONCE) saw a 35% decline. This was due to an increased negative sentiment for the stock. At the American Society of Hematology’s (ASH) annual meeting, ONCE presented rather disappointing data on their trials of their experimental drug to treat Hemophilia-A. Spark’s data showed that though its therapy reduced bleeding, the drug [&hellip;]<!-- AddThis Advanced Settings generic via filter on get_the_excerpt --><!-- AddThis Share Buttons generic via filter on get_the_excerpt --></p> . A Global Investing Platform helping investors from India & Middle East invest in US listed
We care about your data, and we'd love to use cookies to make your experience better.